<p>蒙特利爾，魁北克 --（Newsfile Corp. -2026 年 2 月 10 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（&#34;Defence&#34;或&#34;公司&#34;），一家公開交易的生物技術和精準細胞內藥物遞送公司，報告了其於 2026 年 1 月 30 日舉行的科學顧問委員會（&#34;SAB&#34;）會議，會議重點討論了 Accum®在抗體藥物偶聯物（&#34;ADC&#34;）應用中的戰略定位。</p>
<p>此次討論匯聚了在 ADC 化學與開發、實驗設計與轉化科學、價值創造與合作戰略等領域的互補專業知識，使得對 Accum®在改善 ADC 藥物載荷細胞內遞送中的作用進行了深入且富有建設性的交流。討論集中在識別最關鍵的科學問題、細化開發優先事項以及將數據生成與未來臨牀和製藥合作伙伴的期望對齊。</p>
<p>&#34;這次討論極具價值，幫助我們明確了科學重點和戰略方向，&#34; Defence Therapeutics 的首席科學官 Maxime Parisotto 博士表示。&#34;我們的顧問分享的見解直接影響了我們設計下一步研究的方式，確保我們生成對推進 Accum®進入臨牀和為平台建立有意義的合作關係最重要的數據。&#34;</p>
<p>此次討論受益於 Rob Leanna 博士的互補專業知識，他在 AbbVie 的長期任職期間積累了 ADC 開發、藥物連接化學和臨牀推進方面的經驗；Danny Chui 博士則帶來了在 Zymeworks、Abdera Therapeutics 和 Kairos Therapeutics 的重大工作所提供的對 ADC 設計和轉化科學的深刻見解；Brendan Hussey 博士則從臨牀開發、戰略和資本形成的角度貢獻了價值創造與合作的視角。他們的意見共同指導了 Accum®開發的下一個階段，推動平台向臨牀轉化和戰略合作伙伴關係發展。</p>
<p>通過這次多學科的對話，Defence Therapeutics 正在細化其 Accum® ADC 開發路線圖，以更好地將平台能力與臨牀開發要求和合作考慮對齊，目標是實現更有效且耐受性更好的 ADC 療法。這一方法強化了 Accum®作為複雜生物製劑下一代細胞內遞送解決方案的潛力。如需探索合作機會或安排會議，請聯繫 info@defencetherapeutics.com。</p>
<p><strong>關於 Defence Therapeutics：</strong></p>
<p>Defence Therapeutics 是一家公開交易的生物技術公司，致力於使癌症治療更加有效和安全。通過其 Accum®精準藥物遞送平台，Defence 正在努力提高 ADC 和其他複雜生物製劑在較低劑量下的效力，旨在減少副作用並改善對先進療法的獲取。通過追求前沿科學，並與製藥和生物技術合作伙伴合作，Defence 力求為最需要的患者帶來變革性療法。欲瞭解更多關於 Defence Therapeutics 的信息並探索合作機會，請訪問 www.defencetherapeutics.com 或聯繫 info@defencetherapeutics.com。</p>
<p><strong>關於 “前瞻性” 信息的警示聲明</strong></p>
<p>本發佈包含某些可能被視為 “前瞻性聲明” 的內容。除歷史事實外，本發佈中的所有聲明，涉及公司預期發生的事件或發展，均為前瞻性聲明。前瞻性聲明是指非歷史事實的聲明，通常但不總是通過 “預期”、“計劃”、“預計”、“相信”、“打算”、“估計”、“項目”、“潛在” 等詞語或 “將”、“會”、“可能”、“可以” 或 “應該” 發生的事件或條件來識別。儘管公司相信這些前瞻性聲明中表達的期望基於合理假設，但這些聲明並不保證未來的表現，實際結果可能與前瞻性聲明中的結果有實質性差異。可能導致實際結果與前瞻性聲明中的結果有實質性差異的因素包括監管行動、市場價格、資本和融資的持續可用性，以及一般經濟、市場或商業條件。投資者被警告，任何此類聲明都不保證未來的表現，實際結果或發展可能與前瞻性聲明中預測的結果有實質性差異。前瞻性聲明基於公司管理層在聲明發布時的信念、估計和意見。除適用證券法要求外，公司沒有義務在管理層的信念、估計或意見或其他因素髮生變化時更新這些前瞻性聲明。</p>
<p>CSE 及其市場監管機構（根據 CSE 政策的定義）對本發佈的充分性或準確性不承擔責任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg"/></p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/282529</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282529/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282529/375"/></p>

動態生物技術與基因組 ETF - Invesco

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Defence Therapeutics Inc. 於 2026 年 1 月 30 日召開了科學顧問委員會會議，以推進其 Accum® ADC 戰略。專家們討論了 ADC 化學、開發和臨牀合作伙伴關係，完善了 Accum® 的開發路線圖，以增強 ADC 荷載的細胞內遞送。獲得的見解將為未來的研究提供信息，並與臨牀和製藥合作伙伴的期望保持一致。Defence 旨在提高 ADC 療法的有效性和耐受性，將 Accum® 定位為癌症治療的下一代解決方案。如需合作諮詢，請聯繫 info@defencetherapeutics.com</p>

<p>Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board (&#34;SAB&#34;) meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate (&#34;ADC&#34;) applications.</p>
<div class="lb-trans"><p>蒙特利爾，魁北克 --（Newsfile Corp. -2026 年 2 月 10 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（&#34;Defence&#34;或&#34;公司&#34;），一家公開交易的生物技術和精準細胞內藥物遞送公司，報告了其於 2026 年 1 月 30 日舉行的科學顧問委員會（&#34;SAB&#34;）會議，會議重點討論了 Accum®在抗體藥物偶聯物（&#34;ADC&#34;）應用中的戰略定位。</p>
</div><p>The discussion brought together complementary expertise spanning ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth and highly constructive exchange on Accum®'s role in improving intracellular delivery of ADC payloads. The conversation focused on identifying the most critical scientific questions to address, refining development priorities, and aligning data generation with the expectations of future clinical and pharmaceutical partners.</p>
<div class="lb-trans"><p>此次討論匯聚了在 ADC 化學與開發、實驗設計與轉化科學、價值創造與合作戰略等領域的互補專業知識，使得對 Accum®在改善 ADC 藥物載荷細胞內遞送中的作用進行了深入且富有建設性的交流。討論集中在識別最關鍵的科學問題、細化開發優先事項以及將數據生成與未來臨牀和製藥合作伙伴的期望對齊。</p>
</div><p>&#34;This was an exceptionally valuable discussion that helped us sharpen both our scientific focus and our strategic direction,&#34; said Maxime Parisotto, PhD, Chief Scientific Officer of Defence Therapeutics. &#34;The insights shared by our advisors are directly informing how we design our next studies, ensuring that we generate the data that matter most to advance Accum® toward the clinic and position the platform for meaningful partnerships.&#34;</p>
<div class="lb-trans"><p>&#34;這次討論極具價值，幫助我們明確了科學重點和戰略方向，&#34; Defence Therapeutics 的首席科學官 Maxime Parisotto 博士表示。&#34;我們的顧問分享的見解直接影響了我們設計下一步研究的方式，確保我們生成對推進 Accum®進入臨牀和為平台建立有意義的合作關係最重要的數據。&#34;</p>
</div><p>The discussion benefited from the complementary expertise of Rob Leanna, PhD, whose experience in ADC development, drug-linker chemistry, and clinical advancement was shaped through his long tenure at AbbVie; Danny Chui, PhD, who brought deep insight into ADC design and translational science informed by his significant work at Zymeworks, Abdera Therapeutics, and Kairos Therapeutics; and Brendan Hussey, PhD, who contributed a value-creation and partnering perspective grounded in clinical development, strategy, and capital formation. Together, their input is guiding the next phase of Accum® development as the platform advances toward clinical translation and strategic partnerships.</p>
<div class="lb-trans"><p>此次討論受益於 Rob Leanna 博士的互補專業知識，他在 AbbVie 的長期任職期間積累了 ADC 開發、藥物連接化學和臨牀推進方面的經驗；Danny Chui 博士則帶來了在 Zymeworks、Abdera Therapeutics 和 Kairos Therapeutics 的重大工作所提供的對 ADC 設計和轉化科學的深刻見解；Brendan Hussey 博士則從臨牀開發、戰略和資本形成的角度貢獻了價值創造與合作的視角。他們的意見共同指導了 Accum®開發的下一個階段，推動平台向臨牀轉化和戰略合作伙伴關係發展。</p>
</div><p>As a result of this multidisciplinary dialogue, Defence Therapeutics is refining its Accum® ADC development roadmap to better align platform capabilities with clinical development requirements and partnering considerations, with the goal of enabling more effective and better-tolerated ADC therapies. This approach reinforces Accum®'s potential as a next-generation intracellular delivery solution for complex biologics. To explore partnering opportunities or schedule a meeting, please contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>通過這次多學科的對話，Defence Therapeutics 正在細化其 Accum® ADC 開發路線圖，以更好地將平台能力與臨牀開發要求和合作考慮對齊，目標是實現更有效且耐受性更好的 ADC 療法。這一方法強化了 Accum®作為複雜生物製劑下一代細胞內遞送解決方案的潛力。如需探索合作機會或安排會議，請聯繫 info@defencetherapeutics.com。</p>
</div><p><strong>About Defence Therapeutics:</strong></p>
<div class="lb-trans"><p><strong>關於 Defence Therapeutics：</strong></p>
</div><p>Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>Defence Therapeutics 是一家公開交易的生物技術公司，致力於使癌症治療更加有效和安全。通過其 Accum®精準藥物遞送平台，Defence 正在努力提高 ADC 和其他複雜生物製劑在較低劑量下的效力，旨在減少副作用並改善對先進療法的獲取。通過追求前沿科學，並與製藥和生物技術合作伙伴合作，Defence 力求為最需要的患者帶來變革性療法。欲瞭解更多關於 Defence Therapeutics 的信息並探索合作機會，請訪問 www.defencetherapeutics.com 或聯繫 info@defencetherapeutics.com。</p>
</div><p><strong>Cautionary Statement Regarding &#34;Forward-Looking&#34; Information</strong></p>
<div class="lb-trans"><p><strong>關於 “前瞻性” 信息的警示聲明</strong></p>
</div><p>This release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</p>
<div class="lb-trans"><p>本發佈包含某些可能被視為 “前瞻性聲明” 的內容。除歷史事實外，本發佈中的所有聲明，涉及公司預期發生的事件或發展，均為前瞻性聲明。前瞻性聲明是指非歷史事實的聲明，通常但不總是通過 “預期”、“計劃”、“預計”、“相信”、“打算”、“估計”、“項目”、“潛在” 等詞語或 “將”、“會”、“可能”、“可以” 或 “應該” 發生的事件或條件來識別。儘管公司相信這些前瞻性聲明中表達的期望基於合理假設，但這些聲明並不保證未來的表現，實際結果可能與前瞻性聲明中的結果有實質性差異。可能導致實際結果與前瞻性聲明中的結果有實質性差異的因素包括監管行動、市場價格、資本和融資的持續可用性，以及一般經濟、市場或商業條件。投資者被警告，任何此類聲明都不保證未來的表現，實際結果或發展可能與前瞻性聲明中預測的結果有實質性差異。前瞻性聲明基於公司管理層在聲明發布時的信念、估計和意見。除適用證券法要求外，公司沒有義務在管理層的信念、估計或意見或其他因素髮生變化時更新這些前瞻性聲明。</p>
</div><p>Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>CSE 及其市場監管機構（根據 CSE 政策的定義）對本發佈的充分性或準確性不承擔責任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8000/282529_ea22eb4d94dabb52_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282529</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/282529</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/282529/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/282529/375"/></p>

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board | DTCFF Stock News

StockTitan

美國制藥 ETF - iShares

醫藥突破 ETF - ALPS

Solo Brands

Therapeutics MD

Turn Therapeutics

醫療業 ETF - Vanguard

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

標普全球醫療股指數 ETF - iShares

醫療業 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

Defence Therapeutics 通過多學科科學顧問委員會調整其累積 ADC 策略 | DTCFF 股票新聞